Docusate

What it is

A detergent-type molecule sold over the counter as a stool softener, usually as docusate sodium 50 or 100 mg soft gels, capsules or liquid, and also as docusate calcium. It is also used as a rectal liquid or enema, often combined with sorbitol, and as an ear-drop cerumenolytic. It was patented in 1937, before the modern drug-approval requirements existed, which is part of why its efficacy was never established by registration trials.

What the research says

The claim is that it draws water and fat into the stool so the stool softens and straining eases. The evidence for that in adults is largely negative. A randomised double-blind trial in hospice patients found no benefit of docusate added to sennosides over placebo added to sennosides on stool frequency, volume or consistency. A randomised trial against psyllium found psyllium increased stool water content while docusate essentially did not (2.33 percent versus 0.01 percent). A randomised trial after rotator cuff surgery found constipation just as common with docusate as with nothing. A 2021 review of the older-adult literature concluded docusate showed no benefit against placebo, psyllium or sennosides. One 2025 retrospective study in hospitalised children found 67 percent had a bowel movement within 72 hours, no different from polyethylene glycol - the clearest positive signal and a non-randomised one. As an ear-wax softener it has randomised support, though Cochrane rates the whole cerumenolytic literature low quality.

Evidence grade: Not supported by the research.

How it works

Drug class: Surfactant (anionic detergent) stool softener, classified on the label as a stool softener laxative; available over the counter

It is a detergent. It lowers the surface tension at the boundary between water and fat in stool, which lets water and fat mix into the stool mass instead of staying separate, in theory softening it. That is the proposed mechanism; it is worth separating the mechanism from the outcome, because the mechanism is plausible and the trials that measured stool water in people mostly did not find the softening the mechanism predicts. (Source 1)

What it is used for

• The over-the-counter label claims relief of occasional constipation with a bowel movement generally in 12 to 72 hours. The randomised evidence does not bear that out: a placebo-controlled hospice trial found no difference, a head-to-head trial found psyllium superior on stool water content and total output, and a 2021 review of the older-adult trials concluded docusate showed no benefit against placebo, psyllium or sennosides. Evidence: not-supported. (Source 2)
• In a randomised trial after rotator cuff repair, 71.4 percent of the docusate group were constipated against 64.3 percent of the no-treatment control (p=0.88), with no difference in symptom or quality-of-life scores at any point over six weeks. A separate randomised trial in women on routine docusate after urogynaecological surgery found adding polyethylene glycol did not shorten time to first bowel movement either. Evidence: not-supported. (Source 3)
• The Cochrane review of laxatives in palliative care identified five small trials, could not meta-analyse them, and found no evidence that any individual laxative was more effective than another or caused fewer adverse effects. A systematic review of seven long-term-care trials in 444 patients found senna superior to or as effective as the alternatives. Evidence: not-supported. (Source 4)
• A retrospective study of 7,581 medical inpatients found 28 percent of patients receiving opioids got either no laxative or docusate on its own, and framed docusate as a drug of known ineffectiveness that should be deprescribed. No randomised trial supports docusate monotherapy for this. Evidence: not-supported. (Source 5)
• One 2025 retrospective multicentre study of 180 hospitalised children found a bowel movement within 72 hours in 66.67 percent on docusate against 71.11 percent on polyethylene glycol 3350 (p=0.5196), with no difference in time to first bowel movement. It is retrospective, the groups differed at baseline, and the authors themselves call for a prospective trial. Evidence: limited. (Source 6)
• In a randomised trial of 91 patients with complete cerumen occlusion, docusate cleared the canal in 82.61 percent against 91.11 percent for 2.5 percent sodium bicarbonate (success ratio 1.10, 95% CI 0.94-1.29, p=0.23). The Cochrane review of ear drops found no high-quality evidence that any one cerumenolytic beats another, or that active drops beat water or saline. Evidence: limited. (Source 7)
• In a randomised single-blind trial in 77 children, a docusate-and-sorbitol enema emptied the bowel in 88 percent and relieved symptoms in 73 percent - the active control arm against which free fatty acid suppositories were tested. This is the rectal route, not the oral stool softener, and should not be read across to the capsules. Evidence: limited. (Source 8)

Interactions

• Mineral oil (liquid paraffin) (label): The over-the-counter label's only 'do not use' is mineral oil, unless a doctor says otherwise. The concern in the literature is that docusate, being a surfactant, can increase absorption of mineral oil from the gut, which is where the systemic risk of mineral oil lies. (Source 9)
• Sennosides (senna) in fixed-dose combination products such as Senna-S and Peri-Colace (clinical trial): This is the commonest combination, and the best test of it is negative: in a randomised double-blind trial in hospice patients, docusate plus sennosides did no better than placebo plus sennosides on stool frequency, volume, consistency, difficulty or completeness of evacuation. In other words the docusate component contributed nothing measurable on top of the senna. (Source 10)
• Polyethylene glycol 3350 (Miralax, Movicol) (clinical trial): Adding one to the other has been tested twice and neither test showed a gain. In hospitalised children the two were equally effective head to head, with slightly more diarrhoea on polyethylene glycol. There is no documented pharmacokinetic interaction, only an absence of additive benefit. (Source 6)
• Psyllium (ispaghula husk), a fibre supplement (clinical trial): Not an interaction so much as a direct comparison that docusate loses: in a randomised double-blind trial in 170 adults, psyllium increased stool water content, stool water weight and total stool output significantly more than docusate. Taking docusate instead of a bulking fibre is the documented downside. (Source 11)
• Sorbitol (in the docusate-plus-sorbitol enema) (clinical trial): The rectal product combines docusate with sorbitol 70 percent, and in that form it emptied the bowel in 88 percent of children in a randomised trial. The effect of the combination should not be attributed to the docusate alone, and it should not be read across to the oral capsules. (Source 8)
• Alcohol (label): No alcohol interaction is recorded on the over-the-counter label or in the trials and reviews we read. The label's warnings are about mineral oil, abdominal symptoms, rectal bleeding and length of use. Treat this as an absence of documented evidence. (Source 12)
• Other supplements and foods (calcium, iron, magnesium, St John's wort, grapefruit, vitamin K, fish oil, turmeric, red yeast rice) (label): We found no documented interaction between docusate and any of these. Docusate acts in the gut lumen as a surfactant rather than through the liver enzymes those supplements affect. The one documented food-type concern remains mineral oil. Note that liquid docusate's safety problem has not been a chemical interaction at all but bacterial contamination of the product in manufacture. (Source 13)

Stopping it

• There is no dependence or withdrawal syndrome described for docusate. The label's own limit is one week of self-treatment: needing a stool softener for longer than that is a reason to see a doctor, as is rectal bleeding or failure to have a bowel movement. (Source 14)
• Because the evidence of benefit is so thin, the literature treats docusate as a drug to stop rather than to taper. A study of 7,581 medical inpatients described it as a good target for deprescription and found only 13 percent of patients already on it had it stopped during admission, with a third of new users started at discharge. (Source 5)
• Stopping it does not appear to cost anything in the trials, because the trials did not find a benefit to lose: in the hospice trial stool frequency, volume and consistency were the same with docusate and with placebo on top of sennosides, and in the surgical trial constipation was as common on docusate as on nothing. (Source 3)

What goes wrong

Contaminated liquid docusate caused a multistate Burkholderia cepacia complex outbreak, with 108 infected patients across 12 states traced to water used in manufacture. (Source 15)

• Case series, Moderate certainty.
• Size: 108 case patients in 12 states.
• Who: critically ill hospitalised adult and paediatric patients.
• How long: 1 January to 31 October 2016.
• Result: two distinct Burkholderia cepacia complex strains from patient cultures were indistinguishable from or closely related to two strains cultured from water used to produce liquid docusate and from product released to the market by the manufacturer.
• Funding: Intramural CDC; authors reported no conflicts of interest.

Limit of this finding: This is an outbreak investigation, so it shows that a contaminated batch of one liquid product caused infections in susceptible hospital patients; it is not evidence about docusate the molecule, and it carries no rate of infection for ordinary use.

These strains were found to be indistinguishable or closely related to 2 strains of Bcc obtained from cultures of water used in the production of liquid docusate, and product that had been released to the market by manufacturer X. CONCLUSIONS: This investigation highlights the ability of bacteria present in nonsterile, liquid drugs to cause infections or colonization among susceptible patients. Prompt reporting and thorough investigation of potentially related infections may assist public health officials in identifying and removing contaminated products from the market when lapses in manufacturing occur.

The index hospital outbreak involved 24 paediatric intensive care patients, 17 with symptomatic infection, and led to a national alert and voluntary recall. (Source 16)

• Case series, Moderate certainty.
• Size: 24 patients; 18 respiratory, 5 blood, 4 urine and 3 stool cultures positive.
• Who: paediatric patients without cystic fibrosis in the paediatric and cardiovascular intensive care units of a 629-bed tertiary paediatric hospital in Houston, Texas; median age 22.5 months (range 2-148 months)
• How long: February through July 2016.
• Result: 17 of 24 patients had symptomatic infections and 7 were colonised; 21 of 24 cases were the same strain, a novel species within the Burkholderia cepacia complex; product cultures of liquid docusate grew an identical strain.
• Funding: not stated.

Limit of this finding: The culture counts in this outbreak report are numbers of isolates, not numbers of patients: 18 respiratory, 5 blood, 4 urine and 3 stool cultures come to 30 isolates among 24 patients, so some patients were positive at more than one site. The recall was a voluntary one by the manufacturer of the liquid docusate; it was not an FDA-ordered recall.

Among the 24 patients, 17 had symptomatic infections and 7 were colonized. The median age of the patients was 22.5 months (range, 2-148 months). Rep-PCR typing showed that 21 of 24 cases represented the same strain, which was identified as a novel species within the B. cepacia complex. Product cultures of liquid docusate were positive with an identical strain of B. cepacia complex. Local and state health departments, as well as the CDC and FDA, were notified, prompting a multistate investigation. CONCLUSIONS Our investigation revealed an outbreak of a unique strain of B. cepacia complex isolated in clinical specimens from non-CF pediatric patients and from liquid docusate. This resulted in a national alert and voluntary recall by the manufacturer.

Docusate prescribing persisted widely in hospital despite the evidence, with a third of patients newly started on it at discharge. (Source 5)

• Cohort study, Low certainty.
• Size: 7,581 admitted patients screened; random sample of 500 docusate recipients, 452 analysed.
• Who: internal medicine inpatients at two urban academic hospitals.
• How long: one year.
• Result: 15% (1169/7581) of admitted patients received at least one dose; of those on it before admission, only 13% (31/238) had it stopped; 33.2% (71/214) of those not previously on it were newly prescribed it at discharge; 28% (51/185) of patients on opioids got no laxative or docusate monotherapy.
• Funding: not stated.

Limit of this finding: The paper contradicts itself on one figure. Its conclusions say "Among patients already receiving docusate, 80% had it continued on discharge", but its results report that only 13 percent (31 of 238) had docusate stopped, which works out at 87 percent continued, not 80 percent. The abstract never defines which denominator the 80 percent uses. Treat the direction of the finding - most people stay on it - as sound and the exact percentage as uncertain.

Docusate was frequently prescribed to medical inpatients despite its known ineffectiveness, with low deprescription and high numbers of new prescriptions. Docusate use was common even among patients at high risk of constipation. One third of patients not receiving docusate before admission were prescribed docusate on discharge, potentially exacerbating polypharmacy. Among patients already receiving docusate, 80% had it continued on discharge, indicating significant missed opportunities for deprescribing. Given the availability of effective alternatives, our results suggest that quality-improvement initiatives are needed to promote evidence-based laxative use in hospitalized patients.

In the paediatric comparison, loose stools and diarrhoea were no more common with docusate than with polyethylene glycol, and if anything less so. (Source 17)

• Cohort study, Low certainty.
• Size: 180 children, 90 per group.
• Who: hospitalised children with acute constipation.
• How long: first days of treatment during admission.
• Result: loose stools 3.33% in each group (p = 1); frank diarrhoeal episodes 15.56% on polyethylene glycol versus 6.67% on docusate (p = 0.0578)
• Funding: no financial support received.

Limit of this finding: The diarrhoea difference did not reach the usual threshold (p = 0.0578) and the authors note in their Discussion that the study "may not have been powered to show a statistical difference of adverse affects between groups", so this should not be read as docusate causing less diarrhoea than polyethylene glycol.

Loose stools were reported similarly between groups (3.33% per group; p = 1). There were more frank diarrheal episodes in patients in the PEG-3350 group vs. the docusate group (15.56% and 6.67%, respectively; p = 0.0578)

The over-the-counter label's own stop-use instruction is a harm signal: rectal bleeding or failure to have a bowel movement after using a laxative could indicate a serious condition, and use beyond one week should prompt a doctor's review. (Source 14)

• Official position, Certainty not rated.
• Size: not applicable (OTC Drug Facts)
• Who: members of the public using it without prescription.
• How long: stated limit of one week of self-treatment.
• Result: no rates given; the label also says not to use it alongside mineral oil unless told to by a doctor, and to ask a doctor first with stomach pain, nausea, vomiting or a sudden change in bowel habits lasting over 2 weeks.
• Funding: manufacturer OTC label; Drug Facts version effective 24 August 2026.

you have rectal bleeding or fail to have a bowel movementafter use of a laxative. These could be signs of a serious condition.

What the evidence supports

A retrospective study in hospitalised children found a bowel movement within 72 hours in two thirds of those given oral docusate, no different from polyethylene glycol. (Source 6)

• Cohort study, Low certainty.
• Size: 180 patients, 90 per group.
• Who: hospitalised children aged 1 month to 18 years with acute constipation, excluding prior laxative use, neurological impairment, Hirschsprung's disease, cystic fibrosis and several other conditions.
• How long: first 72 hours after drug administration, within admissions of at least 72 hours.
• Result: bowel movement within 72 hours: 66.67% docusate versus 71.11% polyethylene glycol 3350 (p = 0.5196); time to first bowel movement 48.9 versus 45.4 hours (p = 0.3283); loose stools 3.33% in each group (p = 1); frank diarrhoea 6.67% docusate versus 15.56% PEG (p = 0.0578)
• Funding: the authors declare no financial support was received for the research or publication.

Limit of this finding: This was a retrospective record review, not a randomised trial. The authors say so themselves and add that it was "a study in silo and not a head-to-head comparison of the two agents, and as such, baseline demographics between the two groups were not similar" - the docusate children were older and heavier, and the two drugs were chosen for different reasons. A finding of "no difference" from a study like this is weaker than the same finding from a randomised trial.

The primary outcome of a bowel movement occurring within 72 h was achieved in 60 children (66.67%) in the docusate group. In the PEG-3350 group, 64 children (71.11%) achieved a bowel movement within 72 h. There was no difference between groups (p = 0.5196).

In a non-inferiority trial of ear drops for impacted wax, docusate was the comparator and cleared the canal in 83 percent of ears, against 91 percent for 2.5 percent sodium bicarbonate. (Source 7)

• Randomized trial, Low certainty.
• Size: 91 participants with unilateral complete cerumen occlusion.
• Who: patients with complete cerumen occlusion of the ear canal that could not be removed by suction; mean age 48.0 years.
• How long: a single 15-minute application, repeated once if the first attempt failed.
• Result: tympanic membrane completely visible in 38 of 46 (82.61%) with docusate sodium versus 41 of 45 (91.11%) with 2.5% sodium bicarbonate; success ratio 1.10 (95% CI 0.94-1.29, p = 0.23); mean suctioning time 124.13 seconds versus 103.61, mean difference 20.52 seconds (95% CI -10.55 to 51.59)
• Funding: research support, non-US government.

Limit of this finding: The direction of this trial matters: docusate was the established comparator and sodium bicarbonate was the drug under test, so the conclusion "2.5% sodium bicarbonate demonstrated non-inferior efficacy and safety compared with docusate sodium" is a statement about bicarbonate, not an endorsement of docusate. The paper’s recommendation to use "this agent" in clinical practice refers to sodium bicarbonate. The quotation also reproduces the journal’s hair-space characters in "p = 0.23" and "103.61 seconds".

At the end of the treatment, the tympanic membrane was completely visible in 41 (91.11%) subjects treated with 2.5% sodium bicarbonate and 38 (82.61%) subjects treated with docusate sodium, with a 1.10 success ratio between the two groups (95% CI: 0.94-1.29, p = 0.23). The mean successful suctioning time was 103.61 seconds using 2.5% sodium bicarbonate and 124.13 using docusate sodium. The mean difference was 20.52 seconds (95% CI: -10.55-51.59). CONCLUSION: 2.5% sodium bicarbonate demonstrated non-inferior efficacy and safety compared with docusate sodium.

In a single-blind phase two trial in 77 children, the docusate-and-sorbitol enema was the active control and emptied the bowel in 88 percent of the 33 children who received it. (Source 8)

• Randomized trial, Low certainty.
• Size: 77 children, 33 in the docusate-sorbitol enema control arm.
• Who: children aged 1 to 17 presenting to an emergency department in Iceland with constipation.
• How long: single treatment with assessment of bowel emptying and symptom relief.
• Result: bowel emptying 88% in the docusate-sorbitol enema control group versus 39% with lower-dose and 81% with higher-dose free fatty acid suppositories; symptom relief 73% versus 30% and 71%.
• Funding: not stated.

Limit of this finding: The percentages rest on small numbers: 88 percent is roughly 29 of the 33 children in the enema arm, and 81 percent is roughly 17 of 21. The same enema group served as the control for both suppository comparisons, so the two comparisons are not independent. The trial was single-blind and phase two, and its own conclusion covers only the HIGHER suppository dose, not the lower one.

A randomised, controlled, single-blind study was undertaken on 77 children aged between one and 17 who presented to an emergency department in Iceland and were diagnosed with constipation. In stage one, 23 patients were randomised to receive lower dose FFA suppositories or Klyx (n = 33). In stage two, 21 different patients were randomised to receive higher dose suppositories and compared with the same Klyx control subjects. RESULTS: The suppositories were effective at bowel emptying in 39% of the group who received the lower FFA doses and 81% of the group receiving higher doses, compared with 88% in the Klyx control group. Symptom relief was obtained in 30% of the group receiving the lower doses and 71% of the group receiving the higher doses, compared with 73% in the control group.

What the evidence does not support

A randomised double-blind placebo-controlled trial in hospice patients found no benefit from adding docusate to sennosides. (Source 10)

• Randomized trial, Moderate certainty.
• Size: 74 patients randomised (35 docusate, 39 placebo)
• Who: hospice inpatients in Edmonton, Alberta, aged 18 or over, able to take oral medicines, no gastrointestinal stoma, Palliative Performance Scale 20% or more.
• How long: 10 days.
• Result: no significant differences in stool frequency, volume or consistency, nor in difficulty or completeness of evacuation; on the Bristol Stool Form Scale more placebo patients had Type 4 and Type 5 stool while more docusate patients had Type 3 and Type 6 (P=0.01)
• Funding: research support, non-US government; no industry funding stated.

There were neither significant differences between the groups in stool frequency, volume, or consistency, nor in difficulty or completeness of evacuation. On the Bristol Stool Form Scale, more patients in the placebo group had Type 4 (smooth and soft) and Type 5 (soft blobs) stool, whereas in the docusate group, more had Type 3 (sausage like) and Type 6 (mushy) stool (P=0.01). CONCLUSION: There was no significant benefit of docusate plus sennosides compared with placebo plus sennosides in managing constipation in hospice patients.

In a randomised double-blind trial against psyllium, docusate barely changed stool water content while psyllium did. (Source 11)

• Randomized trial, Moderate certainty.
• Size: 170 subjects at multiple sites.
• Who: adults with chronic idiopathic constipation.
• How long: 2-week placebo baseline then 2 weeks of treatment.
• Result: change in stool water content from baseline: psyllium 2.33% versus docusate 0.01% (P=0.007); stool water weight 84.0 versus 71.4 g per bowel movement (P=0.04); total stool output 359.9 versus 271.9 g per week (P=0.005); O'Brien rank score 475.1 versus 403.9 (P=0.002); bowel movements 3.5 versus 2.9 per week in treatment week 2 (P=0.02) but no difference in week 1 (3.3 versus 3.1, P>0.05)
• Funding: research support, non-US government; the trial compared two commercial products and no sponsor is named in the abstract.

Compared to baseline, psyllium increased stool water content vs. docusate (psyllium 2.33% vs. docusate 0.01%, P = 0.007). Psyllium also increased stool water weight (psyllium 84.0 g/BM; docusate 71.4 g/BM; P = 0.04), total stool output (psyllium 359.9 g/week: docusate 271.9 g/week; P = 0.005), and O'Brien rank-type score combining objective measures of constipation (psyllium 475.1; docusate 403.9; P = 0.002). Bowel movement (BM) frequency was significantly greater for psyllium (3.5 BM/week) vs. docusate (2.9 BM/week) in treatment week 2 (P = 0.02), with no significant difference (P > 0.05) between treatment groups in treatment week 1 (3.3 vs. 3.1 BM/week). CONCLUSION: Psyllium is superior to docusate sodium for softening stools by increasing stool water content, and has greater overall laxative efficacy in subjects with chronic idiopathic constipation.

A randomised trial after rotator cuff surgery found constipation just as common on docusate as on nothing at all. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 107 patients randomised to docusate, senna glycoside or no treatment.
• Who: patients undergoing rotator cuff repair on a standardised postoperative protocol.
• How long: bowel diary for postoperative days 0-10, with symptom and quality-of-life questionnaires to 6 weeks.
• Result: constipation prevalence 71.4% docusate, 66.7% senna, 64.3% control (p=.88); neither PAC-SYM nor PAC-QOL scores differed between groups at any time point (p>.05); 67% of all patients were constipated.
• Funding: authors reported no conflicts of interest.

Limit of this finding: The published abstract misspells the drug as "docustate sodium"; that is the journal’s typo and has been left as printed. The denominator is also outside the quoted passage: 107 patients were randomised across three arms, so each group held roughly 35 people - small enough that a p value of .88 tells you little beyond the absence of a large effect.

There was no difference in the prevalence of constipation in the docusate, senna, and control groups (71.4%, 66.7%, and 64.3%, respectively; p = .88). Neither PAC-SYM nor PAC-QOL scores significantly differed between the 3 groups at any time point during 6-week follow-up (p > .05). IMPLICATIONS FOR PRACTICE: The majority (67%) of patients experience postoperative constipation following RCR. Although docustate sodium and senna glycoside are common first-line agents for the treatment of constipation, they are ineffective during the postoperative period.

A review of the randomised evidence in older people concluded docusate showed no benefit against placebo, psyllium or sennosides. (Source 18)

• Expert review, not systematic, Low certainty.
• Size: four studies identified for chronic or general constipation in older people.
• Who: older adults with chronic or general constipation.
• How long: varies by included study.
• Result: no benefits for constipation when docusate was compared with placebo, psyllium or sennosides; psyllium and sennosides were more effective than docusate; no difference between docusate and placebo.
• Funding: not stated.

Limit of this finding: This is a narrative review of four studies with no pooled analysis and no effect sizes, so it should not be read as quantitative evidence. The quotation keeps the source’s own broken grammar ("the data presented that docusate is not effective", "Psyllium and sennosides showed to be more effective").

Docusate when compared with placebo or psyllium or sennosides in these trials did not show any benefits for constipation. Psyllium and sennosides showed to be more effective compared with docusate. No differences found between docusate versus placebo. In summary, there is a lack of data to support the use of docusate for constipation and the data presented that docusate is not effective for use in constipation.

The Cochrane review of laxatives in palliative care, which included docusate, found no evidence that any individual laxative worked better or caused fewer adverse effects than another. (Source 4)

• Systematic review, Very low certainty.
• Size: five randomised trials.
• Who: people receiving palliative care with constipation.
• How long: varies; all small trials.
• Result: no meta-analysis was possible because all five trials compared different laxatives or combinations; study findings were at an unclear risk of bias; laxatives were of similar effectiveness but the evidence remains limited.
• Funding: Marie Curie; one author noted Janssen-Cilag had funded a Marie Curie survey of constipation management, and that Janssen-Cilag does not manufacture or promote laxatives.

There was no evidence on whether individual laxatives were more effective than others or caused fewer adverse effects. AUTHORS' CONCLUSIONS: This second update found that laxatives were of similar effectiveness but the evidence remains limited due to insufficient data from a few small RCTs. None of the studies evaluated polyethylene glycol or any intervention given rectally. There is a need for more trials to evaluate the effectiveness of laxatives in palliative care populations. Extrapolating findings on the effectiveness of laxatives evaluated in other populations should proceed with caution. This is because of the differences inherent in people receiving palliative care that may impact, in a likely negative way, on the effect of a laxative.

A systematic review of laxative trials in long-term care found senna superior to or as effective as the alternatives, with docusate among the comparators. (Source 19)

• Systematic review, Low certainty.
• Size: seven randomised controlled trials, 444 patients.
• Who: long-term care patients with chronic constipation.
• How long: short trials; the review notes their short duration as a limitation.
• Result: senna was superior to or as effective as other laxatives; frequency and severity of adverse drug reactions were generally similar between arms and no serious reactions were reported; long-term efficacy and safety were judged not conclusive.
• Funding: not stated.

Senna and lactulose were the most studied laxatives in LTC patients, and senna was found to be superior to or as effective as other laxatives. Generally, the frequency and severity of adverse drug reactions (ADRs) were similar between the arms of the studies, and no serious ADRs were reported. WHAT IS NEW AND CONCLUSION: Considering the short duration of the trials, the lack of trials including newer laxatives and the low quality of some of the included trials, the long-term efficacy and safety of these laxatives are not conclusive.

In the same paediatric study none of the secondary timing outcomes differed either: no difference at 24, 48, 96 or 120 hours, and no difference in how long the first bowel movement took. (Source 6)

• Cohort study, Low certainty.
• Size: 180 patients, 90 per group.
• Who: hospitalised children aged 1 month to 18 years with acute constipation.
• How long: up to 120 hours after the drug was given.
• Result: no differences between groups at 24, 48, 96 and 120 hours; time to first bowel movement 48.9 h with docusate versus 45.4 h with PEG-3350 (p = 0.3283)
• Funding: the authors declare no financial support was received for the research or publication.

Limit of this finding: A finding of no difference in a retrospective record review with dissimilar groups is not the same as a randomised trial showing the two drugs are equivalent.

There were also no differences between groups in achieving a bowel movement within 24-, 48-, 96- and 120-hour periods. The time to achieve first bowel movement was not different between groups (48.9 h vs. 45.4 h, docusate and PEG-3350, p = 0.3283) (Table 3).

In the authors’ own Conclusion section, not among their results, the paper records that the adult evidence runs the other way and that institutions have removed docusate from their formularies because of it. (Source 20)

• Expert review, not systematic, Low certainty.
• Size: 180 patients in the study; the statement summarises the adult literature.
• Who: hospitalised children, with the authors contrasting their result against adult trials.
• How long: not applicable.
• Result: no effect size; a stated contrast between the paediatric result and the adult evidence base.
• Funding: no financial support received.

Limit of this finding: This passage is from the paper’s Conclusion, where the authors argue a case; it is not a result of the study. The same paragraph goes on to say "We believe docusate has a niche in pediatric patients" - an opinion the study itself did not test. The study found no difference between docusate and polyethylene glycol; it did not show docusate working.

Studies in adults have called into question the efficacy of docusate for the treatment of constipation, leading institutions to remove it from their institutional formulary. Our findings do not match those in the adult population.

In women already taking docusate after urogynaecological surgery, adding polyethylene glycol did not shorten time to first bowel movement. (Source 21)

• Randomized trial, Moderate certainty.
• Size: 145 women randomised, 131 (90%) analysed (66 polyethylene glycol, 65 placebo)
• Who: women after urogynaecological surgery, all receiving twice-daily 100 mg docusate sodium.
• How long: 5 days of study drug after surgery, with questionnaires at 1 week.
• Result: time to first bowel movement 2.77 days (IQR 1.86-3.40) with polyethylene glycol versus 2.92 days (IQR 1.85-4.02) with placebo, P=.25; questionnaire scores, faecal incontinence and urgency similar; the polyethylene glycol group took fewer additional laxatives and was more adherent.
• Funding: not stated (NCT01691742)

Polyethylene glycol 3350 did not significantly reduce time to first bowel movement after surgery compared with placebo (2.77 days [interquartile range 1.86-3.40] compared with 2.92 days [interquartile range 1.85-4.02] P=.25). Women in the PEG3350 group were less likely to take additional laxatives postoperatively, and the PEG3350 group was more adherent to the study drug regimen. Questionnaire scores, fecal incontinence, and urgency were similar between groups. CONCLUSION: In women taking routine docusate sodium after urogynecologic surgery, adding PEG3350 postoperatively did not reduce time to first bowel movement.

Where the evidence is mixed

The Cochrane review of ear drops, which included docusate among the water-based treatments, found all adverse events mild and reported in fewer than 30 participants across the trials. (Source 22)

• Systematic review, Low certainty.
• Size: 10 studies, 623 participants (900 ears); only two studies with 141 participants gave usable adverse-event data.
• Who: adults and children with obstructing or impacted ear wax; nine of the ten studies were more than 15 years old.
• How long: drops applied from 15 minutes up to five days.
• Result: no evidence of a significant difference in adverse effects between types of ear drops; all events mild and in fewer than 30 participants across seven studies; occasional dizziness, unpleasant smell, tinnitus and hearing loss reported; no emergencies or serious adverse effects in any of the 10 studies; low-quality evidence.
• Funding: NIDCD NIH support; the coordinating editor of Cochrane ENT was an author but took no part in the editorial process.

There was no evidence of a significant difference in the number of adverse effects between the types of ear drops in these two studies. We summarised the remaining five studies narratively. All events were mild and reported in fewer than 30 participants across the seven studies (low-quality evidence).Secondary outcomesThree studies reported 'other' adverse effects (how many studies planned to report these is unclear). The available information was limited and included occasional reports of dizziness, unpleasant smell, tinnitus and hearing loss. No significant differences between groups were reported. There were no emergencies or serious adverse effects reported in any of the 10 studies.

Where the research disagrees

Whether docusate softens stool or relieves constipation at all

• The over-the-counter Drug Facts label (Atlantis Consumer Healthcare, version effective 24 August 2026), manufacturer's over-the-counter labelling claim; docusate predates the modern drug-approval requirement, so there were no registration efficacy trials behind it: Uses - relieves occasional constipation (irregularity) - generally produces bowel movement in 12 to 72 hours (Source 2)
• Tarumi and colleagues, randomised double-blind placebo-controlled hospice trial (2013), 10-day randomised, double-blind, placebo-controlled trial in 74 hospice patients; primary outcomes stool frequency, volume and consistency: There was no significant benefit of docusate plus sennosides compared with placebo plus sennosides in managing constipation in hospice patients. Docusate use should be considered on an individual basis. (Source 10)
• McRorie and colleagues, randomised double-blind comparison with psyllium (1998), multi-site randomised double-blind parallel trial in 170 adults with objective stool collection and measurement of stool water content: Psyllium is superior to docusate sodium for softening stools by increasing stool water content, and has greater overall laxative efficacy in subjects with chronic idiopathic constipation. (Source 11)
• Sylvia and colleagues, retrospective paediatric study (Frontiers in Pediatrics 2025), the authors’ Conclusion section in a retrospective multicentre record review of 180 hospitalised children, not randomised, with baseline differences between groups; the authors call for a prospective trial: Studies in adults have called into question the efficacy of docusate for the treatment of constipation, leading institutions to remove it from their institutional formulary. Our findings do not match those in the adult population. (Source 20)

How much

• Reference intake: No reference intake exists; docusate is a medicine, not a nutrient. As a position, the over-the-counter Drug Facts label (version effective 24 August 2026) states adults and children 12 and over take 1 to 6 soft gels of 50 mg daily, children 2 to under 12 take 1 to 3 soft gels daily, and for children under 2 a doctor should be asked. The label also states the product should be taken only by mouth. (Source 23)
• Upper limit: No upper limit is set by any nutrition body. The label's stated maximum for the 50 mg soft gel is 6 soft gels daily for adults and children 12 and over, and 3 daily for children 2 to under 12; the label also sets a time limit, advising a doctor be consulted if a stool softener is needed for more than one week. (Source 23)
• Studied: The hospice trial gave docusate (with sennosides) against placebo (with sennosides) for 10 days in 74 patients. (Source 10)
• Studied: The psyllium comparison gave docusate sodium 100 mg twice daily against psyllium 5.1 g twice daily for 2 weeks after a 2-week placebo baseline, in 170 adults. (Source 11)
• Studied: The urogynaecological surgery trial gave twice-daily 100 mg docusate sodium to all participants, randomising only the added polyethylene glycol 3350 or placebo, for 5 days after surgery. (Source 21)
• Studied: In the paediatric study the docusate children were mostly dosed by age: 58 received capsules, 30 received liquid and 2 received both at different times, and 14 (15.6%) did not receive recommended doses. (Source 24)
• Studied: The cerumen trial applied docusate sodium to the ear canal and left it 15 minutes before suction, repeated once if the first attempt failed, in 91 patients. (Source 7)

A common belief, and what the research shows

The belief: Docusate is the gentle, safe first thing to take for constipation, and it softens stool.

What the research shows: Gentle, yes - serious adverse effects are rare and the trials report few. Effective, no, at least not in adults. The randomised evidence is negative: a placebo-controlled hospice trial found no difference in stool frequency, volume or consistency; a head-to-head trial found psyllium raised stool water content 2.33 percent against docusate's 0.01 percent; and a review of the older-adult trials concluded: In summary, there is a lack of data to support the use of docusate for constipation and the data presented that docusate is not effective for use in constipation. The second misconception is that an over-the-counter laxative cannot hurt you. The liquid formulation caused a multistate Burkholderia cepacia complex outbreak in 2016 with 108 infected patients across 12 states, traced to water used in manufacture, ending in a national alert and recall.

Questions and answers

What is it?

A detergent-type molecule sold over the counter as a stool softener, usually docusate sodium 50 or 100 mg in soft gels, capsules or liquid, and also as docusate calcium. It also comes as a rectal liquid or enema (often with sorbitol) and as ear drops for wax. It was patented in 1937, before modern drug approval existed, which is why no registration efficacy trials sit behind it. (Source 1)

What does it do in the body?

In theory it lowers the surface tension between water and fat in the stool, letting water and fat mix into the stool mass so it softens and is easier to pass. That is the proposed mechanism; the trials that actually measured stool water in people mostly did not find the softening the mechanism predicts. (Source 1)

Is it good or bad for you?

Neither, mostly: it appears to be safe and largely ineffective in adults. Randomised trials found no benefit over placebo in hospice patients, no benefit over no treatment after surgery, and clear inferiority to psyllium on stool water content. A review of the older-adult trials said plainly that it is not effective for constipation. It is not actively harmful at normal doses, but it adds a pill to the regimen and the time spent on it is time not spent on something that works. The one real harm on record was contamination of the liquid product in manufacture. (Source 18)

How do you get more of it?

It is bought over the counter; no food contains it. The label's stated amounts are 1 to 6 of the 50 mg soft gels daily for adults and children 12 and over, 1 to 3 daily for children 2 to under 12, and ask a doctor under 2, taken by mouth only and either as one daily dose or divided. Taking more has not been shown to make it work, because the trials at label doses did not show it working. (Source 23)

If it is harmful, what reduces it?

It is not retained in the body in the way this question usually means, and stopping it is simply stopping the tablets. The literature's framing is deprescribing: a study of 7,581 inpatients called it a good target for deprescription, found only 13 percent of existing users had it stopped during admission, and found a third of patients not on it before admission were newly prescribed it at discharge. (Source 5)

Why might someone be low in it or missing it?

Not applicable - it is a synthetic medicine, so nobody is low in it. The question that does arise is why it fails to work, and the honest answer from the trials is that it may simply not do what it is supposed to: in the psyllium comparison docusate changed stool water content by 0.01 percent from baseline, against 2.33 percent for psyllium. Formulation matters too: the rectal docusate-plus-sorbitol enema has randomised support that the oral capsules do not. (Source 11)

Which whole foods contain it or feed it?

No food contains docusate. For the problem it is meant to treat, the comparator with better randomised evidence is a food-derived fibre: psyllium (ispaghula husk) beat docusate on stool water content, stool water weight, total stool output and bowel-movement frequency in a 170-person double-blind trial. The one food-type thing to avoid alongside it is mineral oil, which the label says not to combine without a doctor's say-so. (Source 11)

What happens if you do not have it?

Based on the randomised evidence, little changes. In the hospice trial stool frequency, volume and consistency were the same whether patients got docusate or placebo on top of sennosides, and after rotator cuff surgery 71.4 percent of the docusate group were constipated against 64.3 percent given nothing. The Cochrane palliative-care review could not show any one laxative beating another. What does matter is the underlying constipation going untreated, which is why the label tells people to see a doctor if they need a stool softener for more than a week. (Source 10)

How can you test for it?

There is no blood or stool test for docusate itself. What the trials measured instead were direct outcomes: stool frequency, the Bristol Stool Form Scale, stool water content and weight by collecting and weighing stool, total stool output per week, and validated questionnaires (PAC-SYM and PAC-QOL). Stool water content measured on collected stool is the most objective of these, and it is the measure on which docusate performed worst. Self-reported bowel diaries are the least reliable and are what most everyday assessment rests on. (Source 11)

References

1. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients. 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
2. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) capsule, liquid filled - Drug Facts, Uses (INDICATIONS & USAGE SECTION). 2026. Read the source
3. Journal of the American Association of Nurse Practitioners. The efficacy of docusate sodium and senna glycoside for the treatment of constipation after rotator cuff repair: A randomized controlled study.. 2021. PMID 33625162, DOI 10.1097/JXX.0000000000000575. Read the source
4. The Cochrane database of systematic reviews. Laxatives for the management of constipation in people receiving palliative care.. 2015. PMID 25967924, DOI 10.1002/14651858.CD003448.pub4. Read the source
5. The American journal of medicine. Missed Opportunity to Deprescribe: Docusate for Constipation in Medical Inpatients.. 2016. PMID 27154771, DOI 10.1016/j.amjmed.2016.04.008. Read the source
6. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients (Results, "Primary and secondary clinical outcomes"). 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
7. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. Cerumenolytic Efficacy of 2.5% Sodium Bicarbonate Versus Docusate Sodium: A Randomized, Controlled Trial.. 2020. PMID 32658399, DOI 10.1097/MAO.0000000000002672. Read the source
8. Acta paediatrica (Oslo, Norway : 1992). Free fatty acid suppositories are as effective as docusate sodium and sorbitol enemas in treating constipation in children.. 2016. PMID 26948070, DOI 10.1111/apa.13394. Read the source
9. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) - Drug Facts, Warnings / Do not use (OTC - DO NOT USE SECTION). 2026. Read the source
10. Journal of pain and symptom management. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients.. 2013. PMID 22889861, DOI 10.1016/j.jpainsymman.2012.02.008. Read the source
11. Alimentary pharmacology & therapeutics. Psyllium is superior to docusate sodium for treatment of chronic constipation.. 1998. PMID 9663731, DOI 10.1046/j.1365-2036.1998.00336.x. Read the source
12. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) - Drug Facts, Ask a doctor before use (OTC - ASK DOCTOR SECTION). 2026. Read the source
13. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) - Drug Facts, Active ingredient / Purpose (OTC - PURPOSE SECTION). 2026. Read the source
14. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) - Drug Facts, Stop use and ask a doctor if (OTC - STOP USE SECTION). 2026. Read the source
15. American journal of infection control. A multistate investigation of health care-associated Burkholderia cepacia complex infections related to liquid docusate sodium contamination, January-October 2016.. 2018. PMID 29329922, DOI 10.1016/j.ajic.2017.11.018. Read the source
16. Infection control and hospital epidemiology. An Outbreak of Burkholderia cepacia Complex Infections Associated with Contaminated Liquid Docusate.. 2017. PMID 28166854, DOI 10.1017/ice.2017.11. Read the source
17. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients (Results, "Adverse events"). 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
18. The Senior care pharmacist. The Role of Docusate for Constipation in Older People.. 2021. PMID 34593092, DOI 10.4140/TCP.n.2021.501. Read the source
19. Journal of clinical pharmacy and therapeutics. Efficacy and safety of laxatives for chronic constipation in long-term care settings: A systematic review.. 2018. PMID 29885259, DOI 10.1111/jcpt.12721. Read the source
20. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients (Conclusion section - the authors' conclusion, not a study result). 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
21. Obstetrics and gynecology. Polyethylene Glycol 3350 and Docusate Sodium Compared With Docusate Sodium Alone After Urogynecologic Surgery: A Randomized Controlled Trial.. 2016. PMID 27500338, DOI 10.1097/AOG.0000000000001565. Read the source
22. The Cochrane database of systematic reviews. Ear drops for the removal of ear wax.. 2018. PMID 30043448, DOI 10.1002/14651858.CD012171.pub2. Read the source
23. DailyMed (US FDA OTC Structured Product Label), Atlantis Consumer Healthcare, Inc.. COLACE (docusate sodium) - Drug Facts, Directions (DOSAGE FORMS & STRENGTHS SECTION). 2026. Read the source
24. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients (Results, docusate dosing and dosage forms). 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source